Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance

Molecular Pharmacology

Volumn 49, Issue 6, 1996, Pages 1122-1130

  Chiba, P ^a   Ecker, G ^a   Schmid, D ^a   Drach, J ^a   Tell, B ^a   Goldenberg, S ^b   Gekeler, V ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; PROPAFENONE;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ARTICLE; CROSS RESISTANCE; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; LIPOPHILICITY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICE; P-GLYCOPROTEIN; PROPAFENONE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0029898576     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Biedler, J. L., T. Chang, M. B. Meyers, R. F. H. Peterson, and B. A. Spengler. Drug resistance in Chinese hamster lung and mouse tumor cells. Cancer Treatment Rep. 67:859-867 (1983).
2. Bradley, G., P F. Juranka, and V. Ling. Mechanism of multidrug resistance. Biochim. Biophys. Acta 948:87-128 (1988).
3. Gollapudi S., M. Reddy, P. Gangadharam, T. Tsuruo, and S. Gupta. Mycobacterium tuberculosis induces expression of P-glycoprotein in promonocytic U1 cells chronically infected with HIV type 1. Biochem. Biophys. Res. Commun. 199:1181-1187 (1994).
4. Riordan, J. R., and V. Ling. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254:12701-12705 (1979).
5. Roninson, I. B., J. E. Chin, K. Choi, P. Gros, D. E. Housman, A. Fojo, D. W. Shen, M. M Gottesman, and I. Pastan. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad Sci. USA 83:4538-4542 (1988).
6. Tsuruo, T. Reversal of multidrug resistance by calcium channel blockers and other agents, in Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (I. B Roninson, ed.). Plenum Publishing, New York, 349-371 (1991).
7. Leyland-Jones, B., W. Dalton, G. A. Fisher, and B. I. Sikic. Reversal of multidrug-resistance in cancer chemotherapy. Cancer 72:3484-3488 (1993).
8. Beck, W. T. Modulators of P-glycoprotein-associated multidrug resistance, in Molecular and Clinical Advances in Anticancer Drug Resistance (R. F. Ozols, ed.). Boston, Kluwer Academic Publ., 151-170 (1991).
9. Sikic, B. I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol. 11:1629-1635 (1993).
10. Raderer, M., and W. Scheithauer. Clinical trials of agents that reverse multidrug resistance: a literature review. Cancer 72:3553-3563 (1993).
11. Klopman, G., S. Srivastava, I. Kolossvary, R. F Epand, N. Ahmed, and R. M. Epand. Structure-activity study and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology. Cancer Res. 52:4121-4129 (1992).
12. Ahkmed, N., A. T. Fojo, S. E. Bates, and S. Scala. Pgp substrate diversity among compounds identified by COMPARE analysis in the NCI drug screen. Proc. Am. Assoc. Cancer Res. 36:339 (1995).
13. Chiba, P., G. Ecker, B. Tell, A. Moser, D. Schmid, and J. Drach. Modulation of PGP-mediated multidrug-resistance by propafenone-analogs. Proc. Am. Assoc. Cancer Res. 35:357 (1994).
14. Chiba, P., S. Burghofer, E. Richter, B. Tell, A. Moser, and G. Ecker. Synthesis, pharmacologic activity and structure-activity relationships of a series of propafenone-related modulators of multidrug-resistance. J. Med. Chem. 38:2789-2793 (1995).
15. Somberg, J. C. Clinical use of class Ic antiarrhythmic drugs, in Antiarrhythmic Drugs (E. M. Vaughan Williams, ed.). Springer-Verlag, Berlin/Heidelberg, 258-263 (1989).
16. Gekeler, V., G. Frese, A. Noller, R. Handgretinger, A. Wilisch, H. Schmidt, C. Muller, R. Dopfer, T. Klingebiel, H. Diddens, H. Probst, and D. Niethammer. Mdr1/P-glycoprotein, topoisomerase and glutathione-S-transferase gene expression in primary and relapsed state adult and childhood leukemias. Br. J. Cancer 66:507-517 (1992).
17. Gekeler V., S. Weger, and H. Probst. MDR1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem. Biophys. Res. Commun. 169:796-802 (1990).
18. Pastan, I., M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford, and M. C. Willington. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA 83:4486-4490 (1988).
19. Gilboa, E., M. A. Eglitis, P. W. Kantoff, and F. Anderson. Transfer and expression of cloned genes using retroviral vectors. Biotechniques 4:504-512 (1986).
20. Drach D., S. Zhao, J. Drach, R. Mahadevia, C. Gattringer, H. Huber, and M. Andreeff. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734 (1992).
21. Jancis, E. M., R. Carbone, K. J. Loechner, and P. S. Dannies. Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells. Mol. Pharmacol. 4351-56 (1992).
22. Lee, J. S., K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A. T. Fojo, and S. E. Bates. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:627-638 (1994).
23. Franke, A., J. Mueller, H. Lietz, W. W. Wiersdorff, H. G. Hege, C. D. Mueller, J. Gries, D. Lenke, G. Von Philipsborn, and M. Raschach. Aminopropanol derivatives of 2′-hydroxy-3-phenylpropio-phenones and therapeutic agents containing them. Eur. Pat. Appl. EP 75:207, March 30 (1983); Chem. Abstr. 99:122033c (1983).
24. Bognar, R., and M. Rakosi. Flavonoids. IV. Reduction of 2′-hydroxychalcone and flavanone. Acta Chim. Acad. Sci. Hung. 13:217-228 (1957).
25. Ghose, A. K., A. Pritchett, and G. M. Crippen. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. III: Modeling hydrophobic interactions. J. Comput. Chem. 9:80 (1988).
26. Belsner, K., M. Pfeifer, and B. Wilffert. Reversed-phase high-performance liquid chromatography for evaluating the lipophilicity of pharmaceutical substances with ionization up to logP = 8. J. Chromatogr. 629:123-134 (1993).
27. Raevsky, O. A., V. Y. Grigor'ev, D. Kireev, and N. S. Zefirov. Complete thermodynamic description of H-bonding in the framework of multiplicative approach. Quant. Struct. Act. Relat. 11:49-63 (1992).
28. Kaye, S. B. P-glycoprotein (P-gp), and drug resistance: time for reappraisal? Br. J. Cancer 67:641-643 (1993).
29. Wadkins, R. M. and P. J. Houghton. The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance. Biochim. Biophys. Acta. 1153:225-236 (1995).